Press Release Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™ 1 hour ago
Press Release Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants Aug 12
Press Release Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants Aug 12